Stem Cell Therapy

Stem cell therapy is a branch of regenerative medicine that exploits the two defining properties of stem cells—self-renewal and the capacity to differentiate into specialised cell types—to repair or replace tissue lost to disease, injury, or congenital defect. The scientific foundation was laid by Ernest McCulloch and James Till in Toronto in 1961, who demonstrated the existence of self-renewing blood-forming cells, and was extended by the work of E. Donnall Thomas, whose pioneering bone-marrow transplants earned the 1990 Nobel Prize in Physiology or Medicine. Stem cells are classified by potency—totipotent (the zygote), pluripotent (embryonic stem cells, capable of forming any of the three germ layers), and multipotent (adult or somatic stem cells such as hematopoietic and mesenchymal cells, with restricted lineage). The 2006 discovery of induced pluripotent stem cells (iPSCs) by Shinya Yamanaka, recognised with the 2012 Nobel Prize, reprogrammed adult somatic cells to a pluripotent state, sidestepping the ethical objections attached to embryonic sources.

The procedural mechanics depend on the cell source and the target pathology. Autologous therapy harvests cells from the patient—typically bone marrow aspiration from the iliac crest, peripheral blood after mobilisation with granulocyte-colony stimulating factor, or adipose tissue—and reinfuses them, eliminating immune rejection. Allogeneic therapy uses a donor, requiring human leukocyte antigen (HLA) matching and post-transplant immunosuppression to prevent graft-versus-host disease. The classic established procedure is hematopoietic stem cell transplantation (HSCT): the recipient undergoes a conditioning regimen of chemotherapy or radiation to ablate diseased marrow, after which donor stem cells are infused intravenously and engraft in the marrow niche, reconstituting the blood and immune systems over several weeks. Cord-blood banking, drawing on the hematopoietic-rich blood of the umbilical cord at birth, supplies an alternative allogeneic source with lower HLA-matching stringency.

Beyond blood disorders, the field encompasses tissue-engineering and cell-replacement strategies. Mesenchymal stem cells are investigated for cartilage, bone, and cardiac repair; iPSC-derived retinal pigment epithelium has been transplanted in macular degeneration trials; and gene-edited stem cells now intersect with CRISPR-Cas9 technology. The 2023 approvals of Casgevy (exagamglogene autotemcel)—the first CRISPR-edited cell therapy, correcting sickle-cell disease and beta-thalassemia by editing autologous hematopoietic stem cells—by the UK MHRA and the US FDA mark the convergence of gene editing and stem cell medicine. Such therapies remain technically demanding, costly, and confined to specialised centres.

In India, stem cell research and clinical application are governed by the National Guidelines for Stem Cell Research (2017), issued jointly by the Indian Council of Medical Research (ICMR) and the Department of Biotechnology, superseding the 2007 and 2013 versions. These guidelines classify research into permissible, restricted, and prohibited categories, mandate Institutional Committee for Stem Cell Research (IC-SCR) oversight, and crucially declare that—apart from HSCT for approved haematological indications—all other stem cell use is investigational and may be administered only within an approved clinical trial. The Drugs and Cosmetics Act and the New Drugs and Clinical Trials Rules, 2019, bring cell-based products under regulatory purview. Globally, the FDA, the European Medicines Agency, and Japan's Pharmaceuticals and Medical Devices Agency—operating under Japan's 2014 Act on the Safety of Regenerative Medicine—provide accelerated but conditional pathways.

Stem cell therapy must be distinguished from adjacent concepts. It is not synonymous with gene therapy, which corrects defective genes (though the two converge in ex-vivo edited cell products); nor with organ transplantation, which replaces whole organs rather than regenerating tissue from progenitor cells. It differs from tissue engineering, which combines cells with scaffolds and bioactive factors to build constructs, and from platelet-rich plasma treatments marketed misleadingly under regenerative branding. The term "stem cell tourism" denotes the cross-border pursuit of unproven, often fraudulent treatments, a distinct phenomenon from legitimate clinical trials.

The field is shadowed by significant ethical and regulatory controversy. The destruction of human embryos to derive embryonic stem cells provoked sustained debate, prompting the US Dickey-Wicker Amendment restricting federal funding and President George W. Bush's 2001 limitation on eligible cell lines, later eased by President Obama's Executive Order 13505 in 2009. A persistent problem is the proliferation of unregulated clinics offering unvalidated "stem cell" infusions for conditions from autism to arthritis; the ICMR has repeatedly warned that no such therapy outside HSCT is approved in India. The 2014 STAP-cell fraud at Japan's RIKEN institute and the 2018 He Jiankui germline-editing scandal underscore the integrity and oversight challenges. Manufacturing standardisation, tumourigenicity of pluripotent cells, and equitable access to multimillion-dollar therapies remain unresolved.

For the working practitioner—whether a civil-services aspirant addressing GS Paper III science-and-technology questions, a health-ministry desk officer, or a policy analyst—stem cell therapy exemplifies the governance tension between rapid biotechnological promise and patient-safety regulation. It demands fluency in the distinction between established procedures (HSCT) and investigational claims, awareness of the ICMR-DBT framework and its prohibition of unapproved commercial offerings, and an understanding of how gene-editing breakthroughs are reshaping the regulatory landscape. The therapy sits at the intersection of public health, ethics, intellectual property, and pharmaceutical policy, making it a recurrent and high-yield theme in examinations and in real-world health diplomacy.